Matias

Unbearable sadness.

Last week, we lost a two-year-old boy, Matias, to cancer. In Hungarian, we would have called him Matyi. His mother has encouraged me to share my thoughts and feelings.

‍

It is impossible for me to accept this as a human being, as a father, and as a cancer researcher.

‍

People often ask me what gives me the strength to continue cancer research every day, after so many decades.

‍

The answer is always the same: patients like him.

‍

I often imagine how I could explain to a child like Matias that I gave up because the work became too difficult, because there were too many failures. I always realize that this would be impossible.

‍

I still remember the little girl who asked me thirty years ago whether we had finally found a treatment so her leg would not need to be amputated. Moments like these stay with you forever.

‍

I have witnessed the entire modern era of precision oncology. I was there when we had no targeted therapies at all. I was there when the first breakthroughs with targeted therapies gave us hope that understanding the molecular drivers of cancer could fundamentally change outcomes for patients.

And it did.

‍

Since the Human Genome Project, medicine has made extraordinary progress. Molecular profiling and targeted therapies have transformed the lives of many patients who previously had no options.

But we have also learned cancer is far more complex than we originally hoped.

Most tumors are not driven by a single genomic alteration. They harbor multiple interacting alterations, often four or five major molecular drivers evolving together within highly adaptive biological systems. Matching one mutation to one drug is often not enough.

‍

This week’s loss painfully reminded me of both how far we have come and how far we still need to go.

‍

Matias was diagnosed before the age of two with a very rare and highly aggressive tumor. Molecular analysis identified a genomic alteration, and after the initial therapies failed, his mother reached out to us for help. Together with my colleagues, we analyzed potential targeted treatment options. Several leading oncology centers agreed with the same recommendation, and he received the therapy.

The treatment worked. The metastases shrank.

For months. Gaining little but precious time.

Then a new tumor emerged. We needed a new biopsy and deeper molecular analysis to understand how the cancer had evolved and which new resistance mechanisms had developed.

But we did not have a chance. 

‍

That is the reality of cancer. Even when we win battles, the disease adapts.

‍

This is why I increasingly believe that the future of oncology requires not only broader access to comprehensive molecular profiling for every patient, but also computational approaches capable of interpreting the full complexity of cancer biology.

‍

But computational systems must be validated against real-world drug-sensitivity and patient-outcome data. Our goal should not be to build systems that merely replicate average human opinion. The standard cannot simply be whether an algorithm agrees with existing clinical intuition.

‍

Our ambition must be far higher.

‍

We should measure success by one criterion above all others: whether we improve patient outcomes.

‍

Cancer is too complex for simplistic solutions. Human cognition alone can no longer fully integrate the enormous amount of genomic and molecular information now available. We need scientifically validated computational tools that help physicians understand the complex genomic architecture of each tumor and support truly personalized treatment decisions. Not to substitute physicians, but to empower them to give patients a better chance.

‍

Most of the time, I write about successes because I want to share hope. But cancer research and patient care are built as much on painful patient stories as on breakthroughs.

‍

The patients we lose should not weaken our determination. They must deepen it.

‍

We must keep Matias in our thoughts forever. 

‍

Matias — and so many others we could not save — make it impossible for us to stop trying, impossible for us to stop hoping.

‍

I want to quote Matias’ mother here, Lucica Antohi: “At least Matias made history in pharmacology with the use of the drug Afatinib against EGFR-KDD, he received when was under 2 years old this drug and did work on metastasis, so that other children facing this disease may now have access and a chance in the future.”